Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01644669Not ApplicableActive Not Recruiting

Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

Role: collaborator

NCT04681677Phase 2Terminated

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

Role: collaborator

NCT04349111Not ApplicableWithdrawn

An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite"

Role: collaborator

NCT01851772Not ApplicableCompleted

Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer

Role: collaborator

All 4 trials loaded